**Core Concept**
Tumour lysis syndrome (TLS) is a life-threatening metabolic disorder that occurs after the treatment of cancer, usually lymphomas and leukemias, as a result of the rapid release of intracellular components into the bloodstream. The management of TLS involves measures to prevent and treat the metabolic abnormalities associated with this condition. **Allopurinol** and **rasburicase** are commonly used to manage the hyperuricemia associated with TLS.

**Why the Correct Answer is Right**
Since the correct answer is not explicitly provided, let's discuss the general management of TLS. **Rasburicase** is a recombinant urate oxidase that breaks down uric acid into allantoin, which is more soluble and easily excreted by the kidneys. **Allopurinol**, on the other hand, inhibits xanthine oxidase, an enzyme involved in the production of uric acid. Both are recommended for the management of TLS.

**Why Each Wrong Option is Incorrect**
**Option A:** Without the actual options, it's challenging to provide specific reasons for their incorrectness. However, in general, any option that does not align with the standard management protocols for TLS, such as the use of **allopurinol** or **rasburicase**, would be considered incorrect.

**Clinical Pearl / High-Yield Fact**
A crucial point in managing TLS is the aggressive hydration and the use of **rasburicase** or **allopurinol** to prevent uric acid nephropathy. Recognizing the symptoms of TLS early and initiating prompt treatment can significantly improve patient outcomes.

**Correct Answer:** D. Alkalinization.